At a Glance
| Feature | Detail |
|---|---|
| Class / structure | Synthetic 39-amino-acid peptide based on the native GIP sequence with a C20 fatty diacid moiety for albumin binding; dual agonist at GIP and GLP-1 receptors |
| Origin | Developed at Eli Lilly as LY3298176 |
| Mechanism | Simultaneous GIP and GLP-1 receptor agonism: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, central appetite suppression, GIP effects on adipose nutrient handling |
| Used for | Type 2 diabetes (Mounjaro), chronic weight management (Zepbound), obstructive sleep apnoea with obesity (US indication) |
| Route | Once-weekly subcutaneous injection (abdomen, thigh or upper arm) |
| Typical dose range | 2.5 mg (initiation) to 15 mg weekly |
| Half-life | ~5 days |
| Evidence level | Strong — the SURMOUNT and SURPASS programmes, a head-to-head against semaglutide, and randomised outcome trials in sleep apnoea, HFpEF and MASH |
| Regulatory status | FDA approved (Mounjaro 2022, Zepbound 2023, OSA indication 2024). EMA approved. Prescription-only in Germany |
| Anti-doping (WADA 2026) | Not prohibited as a class; verify the current list before competition |
Tirzepatide is, as of 2026, the most effective approved weight-loss medicine that exists. That is a statement about one number — roughly 21% mean body weight reduction at the top dose over 72 weeks — but what makes tirzepatide clinically interesting is the breadth of outcome data that followed. Within three years of approval it had positive randomised trials in obstructive sleep apnoea, in heart failure with preserved ejection fraction, and in steatohepatitis with fibrosis. Very few drugs accumulate that kind of record.
The honest verdict: if the goal is depth of weight loss and the patient tolerates a weekly incretin, tirzepatide is the first choice, and the head-to-head trial against semaglutide supports that rather than merely implying it. The caveats are real and unglamorous — gastrointestinal effects during titration, roughly a quarter of lost weight coming from lean tissue, high cost, and complete dependence on continued treatment to hold the result.
This page covers tirzepatide on its own terms. For the strategic question of which agent to choose, the existing semaglutide vs tirzepatide comparison and the retatrutide three-way comparison work through the sequencing logic.
How it works
Tirzepatide engages two incretin receptors with a single molecule. Its backbone derives from GIP (glucose-dependent insulinotropic polypeptide) rather than GLP-1, engineered to also activate the GLP-1 receptor, with a fatty diacid chain for albumin binding and a five-day half-life [1].
The GLP-1 arm does what it does in semaglutide and liraglutide: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, central appetite suppression.
The GIP arm was the surprise. Isolated GIP receptor agonism was long considered either inert or adipogenic — GIP promotes nutrient storage, and GIP receptor antagonism was simultaneously being pursued as an obesity strategy. Combined with GLP-1 agonism the net effect is clearly additive rather than opposing: greater weight loss, greater HbA1c reduction, and in the discovery work a tolerability profile permitting higher total incretin receptor engagement than GLP-1 alone [1]. The mechanism is still debated; the clinical result is not.
One practical implication follows: tirzepatide’s nausea at a given level of weight loss is not obviously worse than semaglutide’s, which is the opposite of what you would predict if more receptor engagement simply meant more side effects.
What the evidence shows
Weight: the SURMOUNT programme
SURMOUNT-1 (Jastreboff, NEJM 2022) randomised 2,539 adults with obesity or overweight without diabetes, mean weight 104.8 kg, mean BMI 38.0, to tirzepatide 5, 10 or 15 mg weekly or placebo for 72 weeks. Mean weight change: −15.0%, −19.5% and −20.9% versus −3.1% on placebo. At least 5% weight loss was achieved by 85–91% on tirzepatide versus 35% on placebo; 50% (10 mg) and 57% (15 mg) lost at least 20% of body weight, versus 3% on placebo [2].
SURMOUNT-3 (Wadden, Nat Med 2023) tested tirzepatide after a 12-week intensive lifestyle intervention in people who had already lost at least 5%. Additional mean weight change from randomisation to week 72 was −18.4% with tirzepatide versus +2.5% with placebo — a 20.8 percentage-point difference on top of the lifestyle loss [3].
SURMOUNT-4 (Aronne, JAMA 2024) is the withdrawal trial and the most important one for setting expectations. After a 36-week lead-in in which participants lost a mean 20.9%, they were randomised to continue tirzepatide or switch to placebo. Over the next 52 weeks the tirzepatide group lost a further 5.5%; the placebo group regained 14.0%. Total change from baseline to week 88: −25.3% versus −9.9% [4].
SURMOUNT-5 (Aronne, NEJM 2025) is the head-to-head: 751 adults randomised to tirzepatide or semaglutide 2.4 mg for 72 weeks. Weight change −20.2% versus −13.7% (P < 0.001); waist circumference −18.4 cm versus −13.0 cm. Tirzepatide produced higher rates of 10%, 15%, 20% and 25% weight loss [5].
Body composition. The DXA substudy of SURMOUNT-1 (Look, Diabetes Obes Metab 2025, n = 160) showed changes from baseline to week 72 of −21.3% body weight, −33.9% fat mass and −10.9% lean mass with tirzepatide, versus −5.3%, −8.2% and −2.6% with placebo. About 75% of weight lost was fat and 25% lean in both groups [6]. That last detail matters: the lean-mass fraction is what happens during weight loss, not a drug-specific toxicity. It is still worth mitigating.
Glycaemia
SURPASS-2 (Frías, NEJM 2021) compared tirzepatide 5, 10 and 15 mg with semaglutide 1.0 mg in type 2 diabetes. HbA1c fell by 2.01, 2.24 and 2.30 percentage points versus 1.86 with semaglutide; all tirzepatide doses were non-inferior and superior, with greater weight reduction as well [7].
SURPASS-CVOT (Nicholls, NEJM 2025) randomised 13,299 people with type 2 diabetes and atherosclerotic cardiovascular disease to tirzepatide or dulaglutide. The primary composite occurred in 12.2% versus 13.1% (HR 0.92, 95.3% CI 0.83–1.01; P = 0.003 for non-inferiority, P = 0.09 for superiority) [8]. Read that carefully: tirzepatide is non-inferior to an agent with established cardiovascular benefit, not superior to it, and this was an active-comparator trial rather than a placebo trial.
Beyond weight and glucose
Obstructive sleep apnoea. SURMOUNT-OSA (Malhotra, NEJM 2024) ran two trials in adults with moderate-to-severe OSA and obesity, mean baseline apnoea-hypopnoea index about 50 events/hour. Mean AHI change at week 52 was −25.3 and −29.3 events/hour with tirzepatide versus −5.3 and −5.5 with placebo [9]. This supported the 2024 OSA indication and is, in my reading, the most clinically transformative of the secondary indications.
Heart failure with preserved ejection fraction. SUMMIT (Packer, NEJM 2025) randomised 731 patients with HFpEF and obesity, median follow-up 104 weeks. Cardiovascular death or a worsening heart-failure event occurred in 9.9% versus 15.3% on placebo (HR 0.62, 95% CI 0.41–0.95), driven by fewer worsening heart-failure events (8.0% vs 14.2%), with a large improvement in KCCQ symptom score [10].
Steatohepatitis. SYNERGY-NASH (Loomba, NEJM 2024) randomised 190 participants with MASH and fibrosis. Resolution of MASH without worsening fibrosis at 52 weeks occurred in 44%, 56% and 62% on 5, 10 and 15 mg versus 10% on placebo [11]. Phase 2 histology rather than an outcome trial, but a strong signal.
Dosing
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
| Goal | Dose | Route | Frequency / timing | Cycle length | Basis |
|---|---|---|---|---|---|
| Initiation (all indications) | 2.5 mg | SC | Once weekly, same day each week, any time of day, with or without food | 4 weeks | Label (Mounjaro / Zepbound) |
| Standard escalation | 5 → 7.5 → 10 → 12.5 → 15 mg, raising by 2.5 mg no sooner than every 4 weeks | SC | Once weekly | To maximum tolerated dose | Label + Trial — Jastreboff 2022, PMID 35658024 |
| Weight-management maintenance | 5, 10 or 15 mg (maximum tolerated) | SC | Once weekly | Indefinite — SURMOUNT-4 shows regain on stopping | Trial — Aronne 2024, PMID 38078870 |
| Type 2 diabetes | 2.5 mg → 5 mg after 4 weeks, then +2.5 mg every ≥4 weeks to glycaemic target, max 15 mg | SC | Once weekly | Indefinite | Label + Trial — Frías 2021, PMID 34170647 |
| Obstructive sleep apnoea with obesity | 10 or 15 mg (maximum tolerated), via standard escalation | SC | Once weekly | 52 weeks studied | Trial — Malhotra 2024, PMID 38912654 |
| HFpEF with obesity | Maximum tolerated, target 15 mg | SC | Once weekly | 104 weeks median in trial | Trial — Packer 2025, PMID 39555826 |
| GI-intolerance titration | Hold each step 6–8 weeks instead of 4; maintain at 5 or 7.5 mg if higher doses are not tolerated | SC | Once weekly | Indefinite | Practice protocol — standard in obesity-medicine practice; 5 mg still gave ~15% loss in SURMOUNT-1 [2] |
| Dose-sparing maintenance (“micro-dosing”, interval extension) | Sub-label weekly doses, or extending the interval to 10–14 days once at goal weight | SC | Weekly to fortnightly | Indefinite | Anecdotal — widely practised for cost; no trial has tested interval extension, and SURMOUNT-4 compared full-dose continuation with stopping, not with less [4] |
Missed doses. If fewer than four days remain until the next scheduled dose, skip it and resume on schedule; otherwise take it as soon as possible. The dosing day can be changed as long as doses stay at least three days apart.
Stacks and combinations commonly used.
- Protein 1.6–2.2 g/kg ideal body weight plus progressive resistance training. With 25% of lost weight coming from lean tissue [6], this is the intervention that most changes body-composition outcomes — the protocol is in preserving muscle on GLP-1 therapy.
- Metformin or SGLT2 inhibitors: routinely combined in diabetes, no tirzepatide dose adjustment needed.
- Insulin or sulfonylureas: reduce those agents first. Hypoglycaemia in this class is almost always combination hypoglycaemia.
- Anti-emetic support during escalation (for example ondansetron as needed) is common practice, as is simply holding the step increase for longer.
- Activin/myostatin-pathway agents such as bimagrumab are in trials for exactly this lean-mass problem — not approved; see bimagrumab plus semaglutide.
- Injection technique, site rotation and needle choice: peptide injection guide.
What people report: what works and what doesn’t
Sources: the trials above, the open community record on r/tirzepatide and r/Zepbound, and published practice guidance on second-generation anti-obesity medications. Community material shows patterns, not proof, and no individual account is treated as evidence.
Reported to work
- Strong, flat appetite suppression and loss of “food noise”, usually from the first or second dose, and described more consistently than for liraglutide.
- Weight loss in the 15–22% range over a year at adequate doses, closely matching SURMOUNT-1. Reports of a plateau at six to nine months followed by renewed loss after a dose step are common and consistent with the titration design.
- Sleep quality improvement — which now has randomised backing in people with OSA [9].
- Reduced alcohol intake and craving generally. Reported very widely across this class; trials are ongoing, and it is not yet an established effect.
- Gastrointestinal effects easing markedly after the first two or three steps.
Mixed or unclear
- Injection-site and “fat shot” theories about absorption: no controlled data.
- Interval extension or dose-sparing for maintenance: widely practised for cost, pharmacokinetically plausible with a five-day half-life, and untested [4].
- Whether tirzepatide is better tolerated than semaglutide. Discontinuation rates in SURMOUNT-5 were broadly similar, and individual experience varies a lot.
- Hair shedding and facial volume loss: reported frequently; both track rapid, large weight loss rather than being drug-specific.
Reported not to work / disappointing
- Keeping weight off after stopping. SURMOUNT-4 quantifies it at 14% regain in a year [4]. The most common disappointment and the most predictable one.
- Expecting the 15 mg result at 2.5 mg. The starting dose is a tolerability step, not a therapeutic dose.
- Pushing through severe vomiting to reach 15 mg. Dose-limiting intolerance is a reason to stay lower; 5 mg still delivered about 15% weight loss in trial [2].
- Compounded and grey-market “tirzepatide” bought online: recurring reports of under-dosing, unexpected potency and dosing errors from unlabelled concentrations. A sourcing problem rather than a drug problem — see peptide sourcing.
What a properly designed trial would still need to show: whether tirzepatide reduces cardiovascular events in obesity without diabetes, as SELECT showed for semaglutide. SURPASS-CVOT was in diabetes and against an active comparator [8]; the obesity question is open.
Safety and side effects
Common. Nausea, vomiting, diarrhoea, constipation, dyspepsia, abdominal pain, injection-site reactions, fatigue, hair thinning. Gastrointestinal events cluster during escalation and are the dominant reason for discontinuation; in the highest-dose arms of trials in this class, discontinuation for adverse events runs at roughly one in five.
Serious but uncommon. Acute pancreatitis; gallbladder disease and cholecystitis, more frequent with rapid weight loss; acute kidney injury secondary to dehydration from vomiting or diarrhoea; hypersensitivity reactions; progression of pre-existing diabetic retinopathy with rapid glycaemic improvement. A boxed warning for thyroid C-cell tumours applies on the basis of rodent data, with no confirmed human signal.
Peri-operative and anaesthetic risk. Delayed gastric emptying raises the risk of pulmonary aspiration under sedation or general anaesthesia. Current anaesthesia guidance generally advises holding weekly agents of this class for about a week before an elective procedure and extending clear-fluid fasting. Tell any anaesthetist you are taking it.
Contraindications. Personal or family history of medullary thyroid carcinoma, MEN2, prior hypersensitivity, pregnancy and breastfeeding. Avoid with a history of pancreatitis or severe gastroparesis. Tirzepatide can reduce the efficacy of oral contraceptives through delayed absorption, so a non-oral method or backup contraception is advised after initiation and after each dose increase.
Monitoring I would want. Weight and waist, HbA1c, renal function, lipids, retinal screening in diabetes, and a body-composition measure in anyone at risk of sarcopenia. In older adults, grip strength or a timed sit-to-stand tracked over time is more informative than the scale.
Legal and regulatory status
United States. FDA approved as Mounjaro for type 2 diabetes (May 2022) and as Zepbound for chronic weight management (November 2023), with an added indication for moderate-to-severe obstructive sleep apnoea in adults with obesity (December 2024). Compounding on shortage grounds is no longer permitted now that the shortage has resolved; products still sold online sit outside that framework entirely.
European Union and Germany. EMA approved as Mounjaro for type 2 diabetes and for weight management; prescription-only (verschreibungspflichtig). As with the rest of the class, weight-management use in Germany is generally self-paid.
Sport. Not currently prohibited by WADA as a class; verify the current list each season — see peptides and WADA rules.
How it fits: tirzepatide against the rest of the class
| Semaglutide 2.4 mg | Tirzepatide 15 mg | Retatrutide 12 mg | Mazdutide 9 mg | |
|---|---|---|---|---|
| Receptors | GLP-1 | GIP + GLP-1 | GIP + GLP-1 + glucagon | GLP-1 + glucagon |
| Peak trial weight loss | ~15% (68 wk) | ~21% (72 wk) | ~24% (48 wk, phase 2) | ~16.7% (60 wk, phase 3, China) |
| Head-to-head evidence | Lost to tirzepatide (SURMOUNT-5) | Won against semaglutide | None vs tirzepatide | None vs tirzepatide |
| CV outcomes | Benefit in T2D and in obesity | Non-inferior to dulaglutide in T2D | Pending | Pending |
| Other indications with RCT data | MASH, CV, knee OA | OSA, HFpEF, MASH | None yet | None yet |
| Approval | FDA / EMA | FDA / EMA | Filed | Approved in China |
Where tirzepatide sits in practice: first-line when depth of weight loss is the priority and cost is manageable; the agent of choice in obesity with obstructive sleep apnoea or HFpEF, where it has specific randomised evidence; and a reasonable next step after an inadequate response to semaglutide, since SURMOUNT-5 suggests the gap is real rather than an artefact of different trial populations.
Where I would not reach for it first: when the dominant problem is established atherosclerotic cardiovascular disease without diabetes, where semaglutide’s SELECT data are the better-matched evidence; in marked sarcopenia, where the lean-mass fraction of weight lost matters more than the headline percentage; and in anyone who cannot sustain treatment indefinitely, because SURMOUNT-4 shows what follows.
Related Articles
- Semaglutide vs Tirzepatide: GLP-1 Therapies Compared — the head-to-head decision in full.
- Retatrutide vs Semaglutide vs Tirzepatide — where triple agonism changes the calculus.
- Mazdutide: The GLP-1/Glucagon Dual Agonist Approved in China — the other dual-agonist design.
- Preserving Muscle on Semaglutide and Tirzepatide — the protein and training protocol.
- Bimagrumab + Semaglutide: Preserving Muscle While Losing Fat — the experimental answer to lean-mass loss.
- Native GLP-1 (7-36 Amide): Why “Pure GLP-1” Fails as a Drug — the pharmacology the class is built on.
Frequently asked questions
How much weight does tirzepatide cause?
In SURMOUNT-1 (2,539 adults without diabetes, 72 weeks), mean weight change was −15.0% on 5 mg, −19.5% on 10 mg and −20.9% on 15 mg versus −3.1% on placebo. Half of those on 10 mg and 57% on 15 mg lost at least 20% of body weight.
Is tirzepatide better than semaglutide?
For weight, yes, on head-to-head data. SURMOUNT-5 randomised 751 adults and found −20.2% with tirzepatide versus −13.7% with semaglutide 2.4 mg at 72 weeks. SURPASS-2 also favoured tirzepatide on HbA1c. Semaglutide retains the stronger cardiovascular outcome dataset in obesity without diabetes.
What is the tirzepatide titration schedule?
2.5 mg weekly for four weeks, then 5 mg for four weeks, then increases of 2.5 mg no sooner than every four weeks as tolerated, up to a maximum of 15 mg weekly. The 2.5 mg step is a tolerability dose, not a treatment dose.
Does tirzepatide cause muscle loss?
Some, yes. DXA data from SURMOUNT-1 showed roughly 75% of the weight lost was fat mass and 25% lean mass — the same proportion as placebo. That makes protein intake and resistance training the key mitigations rather than a reason to avoid the drug.
What conditions besides obesity and diabetes does tirzepatide treat?
Randomised trials show benefit in moderate-to-severe obstructive sleep apnoea with obesity (SURMOUNT-OSA), heart failure with preserved ejection fraction and obesity (SUMMIT), and metabolic dysfunction-associated steatohepatitis with fibrosis (SYNERGY-NASH). Approved indications vary by country.
What happens if you stop tirzepatide?
Weight returns. In SURMOUNT-4, people switched to placebo after a 36-week lead-in regained 14.0% while those continuing tirzepatide lost a further 5.5% — a 19.4 percentage-point difference over the following year.
References
- Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. PMID: 30473097. https://pubmed.ncbi.nlm.nih.gov/30473097/
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-16. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Wadden TA, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909-18. PMID: 37840095. https://pubmed.ncbi.nlm.nih.gov/37840095/
- Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. PMID: 38078870. https://pubmed.ncbi.nlm.nih.gov/38078870/
- Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26-36. PMID: 40353578. https://pubmed.ncbi.nlm.nih.gov/40353578/
- Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-9. PMID: 39996356. https://pubmed.ncbi.nlm.nih.gov/39996356/
- Frías JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-15. PMID: 34170647. https://pubmed.ncbi.nlm.nih.gov/34170647/
- Nicholls SJ, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med. 2025;393(24):2409-20. PMID: 41406444. https://pubmed.ncbi.nlm.nih.gov/41406444/
- Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193-1205. PMID: 38912654. https://pubmed.ncbi.nlm.nih.gov/38912654/
- Packer M, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427-37. PMID: 39555826. https://pubmed.ncbi.nlm.nih.gov/39555826/
- Loomba R, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299-310. PMID: 38856224. https://pubmed.ncbi.nlm.nih.gov/38856224/
- World Anti-Doping Agency. The 2026 Prohibited List, valid 1 January 2026.
